#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell small lymphocytic lymphoma Acquired ATTR amyloidosis Hepatocellular carcinoma Breast angiosarcoma metastatic B precursor type acute leukaemia Anti-myelin-associated glycoprotein antibodies positive Tuberous sclerosis complex Acute graft versus host disease in skin Osteochondrodysplasia B-cell lymphoma recurrent Muscular dystrophy Cardiac arrest Astrocytoma malignant Small intestine leiomyosarcoma Dent's disease More trials…

    Learn about Rare Diseases

    Haemolytic uraemic syndrome – Diagnostics Pituitary-dependent Cushing’s syndrome – Diagnostics Gaucher’s disease type III – Treatment MELAS syndrome – Treatment Turner’s syndrome – Basic Information Progressive supranuclear palsy – Basic Information Short-bowel syndrome – Life with Disease Sarcoidosis – Diagnostics Cytokine release syndrome Sjogren’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Intestifix Cemiplimab Calcium Polystyrene Sulfonate ANGIOTENSIN II Nizatidine Ilofotase Alfa GSKVX000000034798 Dosulepin Hydrochloride Gadoxetic Acid, Disodium CANNABINOL HTL0022537 Gliclazide Rbl015.2 Neridronate Sodium Giredestrant Pentetic Acid Ozanimod Hydrochloride VRDN-003 IHMA-2121908-1 Patritumab Deruxtecan More therapies…

    Learn about Your Condition

    Malignant peritoneal neoplasm Colorectal cancer stage III Procedural hypotension Pancreaticoduodenectomy Langerhans cell sarcoma Liposarcoma recurrent Chorioretinitis Anogenital warts Arrhythmia Ligament sprain Thyroid disorder Ophthalmoplegia Diabetic ketoacidosis Hodgkin's disease Corticobasal degeneration More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Austria Czechia Denmark France Germany Greece +3

  • Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Gemcitabine Hydrochloride
    • Paclitaxel
    Belgium Czechia Denmark Finland France Germany +7

  • Study on the Effects and Safety of Rilzabrutinib for Adults with Graves’ Disease

    Recruiting

    2 1 1
    Investigated Drugs:
    • Rilzabrutinib
    Germany Greece Hungary Italy Spain

  • Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • HAFNIUM OXIDE
    • Cetuximab
    Austria Belgium Czechia France Germany Greece +4

  • Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

    Recruiting

    3 1
    Investigated Drugs:
    • Seladelpar
    Austria Belgium Czechia Denmark France Germany +7

  • Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • SIGVOTATUG VEDOTIN
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Infliximab
    • Mycophenolate Mofetil
    • Pembrolizumab
    Belgium Bulgaria France Germany Greece Ireland +4

  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Adagrasib
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia France Germany +9

  • Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

    Recruiting

    3 1
    Investigated Drugs:
    • OMECAMTIV MECARBIL
    France Germany Greece Italy Poland Spain

  • Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Nvl-655
    • Alectinib Hydrochloride
    Austria Belgium Czechia Denmark France Germany +7
Previous Page
1 … 3 4 5 6 7 … 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!